A model for the enhancement of the primary humoral immune response of rhesus monkeys to marginal or weakly antigenic vaccines is presented. Our procedure used the complexing of formalin-inactivated Venezuelan equine encephalomyelitis (VEE) virus vaccine with specific, homologous, immune gamma globulin (IgG) Conflicting data have been reported concerning the effect of antigen complexed with specific antibody on the immune response. Studies indicated that "sensitization" of certain bacterial antigens with specific antibody resulted in decreased immunogenicity (13, 18, 22) . Enhanced protective effects were observed in other investigations using Proteus and Brucella antigens; however, the relative amounts of antigen and antibody appeared to exercise a pronounced effect on the immunogenic properties of the antigen (6, 12, 14) .
A model for the enhancement of the primary humoral immune response of rhesus monkeys to marginal or weakly antigenic vaccines is presented. Our procedure used the complexing of formalin-inactivated Venezuelan equine encephalomyelitis (VEE) virus vaccine with specific, homologous, immune gamma globulin (IgG) at equivalence. Equivalence was determined by combining the concentrated, isotopically labeled (3H) virus with various concentrations of specific Sephadex-fractionated IgG. Enhancement Conflicting data have been reported concerning the effect of antigen complexed with specific antibody on the immune response. Studies indicated that "sensitization" of certain bacterial antigens with specific antibody resulted in decreased immunogenicity (13, 18, 22) . Enhanced protective effects were observed in other investigations using Proteus and Brucella antigens; however, the relative amounts of antigen and antibody appeared to exercise a pronounced effect on the immunogenic properties of the antigen (6, 12, 14) .
Mice have shown increased antibody titers and more rapid response to tetanus toxoid-complexed antigen (toxoid and hyperimmune tetanus antitoxin), when boostered in 3 days by toxoid, than mice given toxoid alone (9, 23) . It was also found that antigen-antibody complexes at equivalence and in antigen excess elicited optimal immunogenic responses. Further, it was reported (15) that complexes of diphtheria and tetanus toxoids with specific antibody, combined either at equivalence or antigen excess, stimulated sensitized lymphocytes (certain populations of which are generally accepted as the effector cells in humoral antibody synthesis) to a greater extent than antigen alone.
In preliminary studies, we noted that subcutaneous injection of formalin-inactivated Venezuelan equine encephalomyelitis (VEE) virus vaccine complexed with specific antibody enhanced antibody synthesis in the rhesus monkey vis-a-vis vaccine alone. Since these studies did not include equivalence determinations between vaccine and antibody, an investigation was undertaken to determine this parameter by using concentrated and purified antigen (VEE) and specific antibody.
MATERIALS AND METHODS Virus. Formalin-inactivated VEE (TC-83 strain) virus (17) was the antigen used in determining equivalency. The virus was endogenously labeled with tritiated [3H ]amino acids, concentrated, and titrated in NaCl-tris(hydroxymethyl)aminomethane-ethylenediaminetetraacetic acid buffer, pH 7.3, by the method of Pedersen et al. (16) . Pre-formalinization titer of the virus was 1.5 x 1010 plaque-forming units (PFU)/ml, and specific activity of radiolabel was 4.597 x 106 counts per min per ml. Radiolabeled virus was inactivated by the method of Cole et al. (3), using 0.07% formalin for 24 h at 37 C. The Trinidad strain of VEE virus (19) was used in all challenge studies (4 Serological tests. Two-dimensional gel immunodiffusion tests were performed on microscope slides by the method of Crowle (5), using 0.75% agarose, 0.1% Triton, and buffered with sodium Veronal, pH 8.6 . Ten microliters of antigen or antibody was added to each well, and after 24 to 48 h of reaction time, slides were rinsed for 24 h in phosphate-buffered saline and then for 4 h in distilled water. After drying, slides were stained with 0.2% Coomassie brilliant blue R250 in methanol-acetic acid-water (50:7:50) for 15 min and then destained in the same solution without the dye.
The presence of neutralizing antibody was determined by a modification of the plaque reduction neutralization test (PRNT) of Early et al. (7) by using Vero cell monolayer cultures. Sera were inactivated at 56 C for 30 to 45 min and were then diluted and incubated with virus. Serum dilution-virus mixtures were added to cell cultures and followed in 1 h with agar overlay medium. After 48 h of incubation at 37 C, the agar overlay (0.4% ion agar; Colob Laboratories, Inc., Chicago Heights, Ill.) was decanted, and the cell sheet was fixed with ethyl alcohol for 3 min and stained for 3 min with a crystal violet-alcohol solution (10 g of crystal violet-700 ml of ethyl alcohol-300 ml of distilled water). The VEE virus used in the tests was the attenuated TC-83 strain vaccine virus. End points were recorded as the greatest serum dilution giving )N i ET AL.
INFECT (8) was used to determine equivalence of VEE virus vaccine and specific IgG. The 3H-labeled antigen (VEE virus, TC-83 strain) and immunoglobulin fraction of specific hyperimmune antisera have been described above. A standard block titration method was used in which antigen was diluted in saline from 1: 2 to 1: 10,000 with eight intervening dilutions. IgG was diluted in a similar manner from 1:2 to 1:1,000 with five intervening dilutions. Antigen dilutions in 0.25-ml amounts were combined with an equal volume of each IgG dilution in polypropylene tubes (12 by 75 mm). The mixtures were incubated at 37 C for 1 h, followed by an overnight incubation at 4 C. The complexes were then centrifuged at 12,100 x g for 5 min in a Sorvall-refrigerated centrifuge, using an SS34 Sorvall rotor. The supernatant fluids were decanted and the pellets were suspended in 100 ,liters of 0.85% saline by using a Vortex mixer. Supernatant and pellet samples, 100 uliters of each, were then added to 10 ml of a mixture of 1.0 ml of Scintisol-GP in 10 ml of Scintolute cocktail base (Iso-Lab, Inc., Akron, Ohio), and the contents were counted for 3 min each in a Mark II liquid scintillation system (Nuclear Chicago, Chicago, Ill.). Optimal antigen-antibody complexing was expressed as maximum 3H label in the pellet per unit time (counts per minute).
VEE virus-IgG complexes. A 1: 16 dilution (0.5 ml) of inactivated VEE virus vaccine was determined by the Reed-Muench method (20) to be a median effective dose in Swiss mice and rhesus monkeys. To approximate a marginal antigen concentration, a twofold higher dilution (1:32) was utilized in all antigen-antibody complexing unless otherwise stated. Antigen-antibody concentrations followed a 1:5 ratio at equivalence (e.g., antigen 1:32 and antibody 1:160), and antigen and antibody excess occurred at fivefold antibody dilutions above and below that required for equivalence. Antigen concentration was constant throughout the tests. Antibody controls reflected the highest concentration of antibody used in the experimental design (1: 32).
Protection studies. To determine the protective effects of VEE vaccine and vaccine complexed with specific IgG in 21-day-old Swiss mice, groups of 10 mice each were immunized intraperitoneally with 0. Figure 1 shows the densitometer tracings of the electrophoretic pattern of the serum before and after DEAE-Sephadex fractionation. The separation process removed all of the serum proteins except gamma globulin. Protein concentration of the final IgG preparation was 7.0 mg/ml. Immune serum had a PRNT titer of 1: 2,500 before fractionation as measured against 100 PFU of TC-83 strain VEE virus. The IgG showed a fivefold increase in titer (1:12,500) after separation. Using the micro double-diffusion precipitin procedure, the IgG exhibited reacivity against VEE virus envelope antigen. However, the preparation apparently contained no antibodies to VEE core protein antigen (Fig. 2) .
RESULTS
Using the procedure outlined above, optimal equivalence was demonstrated by using antigen at a dilution of 1: 10 and IgG diluted 1:50. Figure 3 shows the titration curve for the antigen-antibody complexes of this dilution series. Corresponding supernatant fractions exhibited the expected inverse curve relationship due to loss of radiolabeled antigen. By using this experimental design, it was also possible to determine that 140 Ag of specific IgG per ml reached equivalency with approximately 1.5 x 10' PFU of virus.
Since the median effective dose of inactivated VEE vaccine for monkeys was 0.5 ml of a dilution of 1:16, a 1:32 dilution was used to approximate a marginal concentration of antigen. Figure 4 shows the primary immune response in four groups of monkeys. Antibody titers in monkeys immunized with the antigenantibody complex at equivalence were demonstrable 4 days after immunization, whereas 11 days were required to detect antibody in the antigen control group. Antibody was detectable in the group given complex in antigen excess by day 7 (Fig. 2) , special immunodiffusion techniques dilution) concentration of antigen at are required. Quantitation with this procedure alence stimulated antibody in monkeys is more difficult than it is in precipitin reactions r than did undiluted antigen. . .
involving soluble antigen and specific antibody test correlation of vaccine protection in (6, 9, 23 (Table 1) . The elicit antibody titers in the rhesus monkey lation between these data and enhanced comparable to titers found after the administraody responses in rhesus monkeys (Fig. 4) is tion of the live vaccine (21) . This is probably rent. Antigen complexed at equivalence in due to the replicatng capacity of the live virus dilutions gave markedly better protection as compared with the obviously limited antiice than nonequivalent complexes and ols. Similarly, in rhesus monkeys antigen- (Fig. 4) , with the demonstrable titer failing to persist beyond day 21. In contrast, live, attenuated VEE virus vaccine has been shown to elicit primary neutralizing antibody in rhesus monkeys by day 6, with a peak titer of approximately 1: 10,000 by day 8 postimmunization (D. E. Hilmas, personal communication). It is apparent that immunization with the live VEE virus vaccine should provide more rapid and persistent immunity as compared with the killed product (4) .
Antibody responses of the monkeys immunized with a marginal concentration of VEE virus vaccine complexed at equivalence with specific IgG were comparable to, and detected 3 days earlier than, those given undiluted vaccine. These titers were considerably higher and persisted over a broader time frame than the group immunized with complexes in antigen excess or the marginal antigen control group. Considering the difference in antigen concentration between the group given complexes at equivalence and those immunized with the undiluted vaccine, it appears that complexing of VEE virus vaccine with specific antibody at equivalence does enhance the primary immune response of rhesus monkeys to this virus.
Studies are now in progress to determine effects of booster doses in rhesus monkeys given the complexed vaccine. Also, since it was shown that the immunological response to a marginal concentration of inactivated VEE virus vaccine was enhanced when complexed at equivalence with specific IgG, the next logical step is to test this concept by using undiluted vaccine both in monkeys (humoral response) and mice (protection). By this method, it may be possible to achieve more rapid and persistent antibody responses with killed products.
